Status:
COMPLETED
Does Hepatitis C Management Protect Egyptian Population Against Severe Corona Virus Disease-2019?
Lead Sponsor:
Zagazig University
Conditions:
Corona Virus Infection
Hepatitis
Eligibility:
All Genders
21-80 years
Brief Summary
Modulation of the renin angiotensin system by the chronic hepatitis C virus treatment either by (Daclatasvir and Sofosbuvir), (Daclatasvir and Sofosbuvir plus Ribavirin), or (Ribavirin and Interferon)...
Detailed Description
The interaction of severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) and the renin angiotensin system (RAS) via angiotensin converting enzyme-2 (ACE-2), the receptor used by the SARS-CoV-2...
Eligibility Criteria
Inclusion
- All consecutive patients who were diagnosed to have COVID-19 and admitted to Zagazig University Hospitals during the period from May 2020 to January 2021
Exclusion
- \-
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2022
Estimated Enrollment :
2106 Patients enrolled
Trial Details
Trial ID
NCT04757272
Start Date
May 1 2020
End Date
July 30 2022
Last Update
September 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zagazig University Hospitals
Zagazig, Sharqia Province, Egypt, 44519